College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China.
J Med Virol. 2023 Jan;95(1):e28281. doi: 10.1002/jmv.28281.
Breast milk has been found to inhibit coronavirus infection, while the key components and mechanisms are unknown. We aimed to determine the components that contribute to the antiviral effects of breastmilk and explore their potential mechanism. Lactoferrin (Lf) and milk fat globule membrane inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related coronavirus GX_P2V and transcription- and replication-competent SARS-CoV-2 virus-like particles in vitro and block viral entry into cells. We confirmed that bovine Lf (bLf) blocked the binding between human angiotensin-converting enzyme 2 and SARS-CoV-2 spike protein by combining receptor-binding domain (RBD). Importantly, bLf inhibited RNA-dependent RNA polymerase (RdRp) activity of both SARS-CoV-2 and SARS-CoV in vitro in the nanomolar range. So far, no biological macromolecules have been reported to inhibit coronavirus RdRp. Our result indicated that bLf plays a major role in inhibiting viral replication. bLf treatment reduced viral load in lungs and tracheae and alleviated pathological damage. Our study provides evidence that bLf prevents SARS-CoV-2 infection by combining SARS-CoV-2 spike protein RBD and inhibiting coronaviruses' RdRp activity, and may be a promising candidate for the treatment of coronavirus disease 2019.
母乳已被发现可抑制冠状病毒感染,但其关键成分和机制尚不清楚。我们旨在确定母乳中具有抗病毒作用的成分,并探讨其潜在机制。乳铁蛋白(Lf)和乳脂肪球膜在体外抑制严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)相关冠状病毒 GX_P2V 和转录及复制型 SARS-CoV-2 病毒样颗粒,并阻止病毒进入细胞。我们证实牛乳铁蛋白(bLf)通过结合受体结合结构域(RBD)阻断了人类血管紧张素转换酶 2 与 SARS-CoV-2 刺突蛋白之间的结合。重要的是,bLf 在纳摩尔范围内体外抑制了 SARS-CoV-2 和 SARS-CoV 的 RNA 依赖性 RNA 聚合酶(RdRp)活性。迄今为止,尚未有生物大分子被报道可抑制冠状病毒 RdRp。我们的结果表明,bLf 在抑制病毒复制中起主要作用。bLf 处理可降低肺部和气管中的病毒载量并减轻病理损伤。本研究提供了证据表明,bLf 通过结合 SARS-CoV-2 刺突蛋白 RBD 并抑制冠状病毒的 RdRp 活性来预防 SARS-CoV-2 感染,可能是治疗 2019 年冠状病毒病的有前途的候选药物。